Lexicon Pharmaceuticals Inc expected to post a loss of 22 cents a share - Earnings Preview

Lexicon Pharmaceuticals

27/02/2024 11:05

* Lexicon Pharmaceuticals Inc  LXRX.OQ   LXRX.O  is expected
to show a rise in quarterly revenue when it reports  results on
February 29 (estimated) for the period ending December 31 2023
    * The The Woodlands Texas-based  company is expected to
report a
4,334.8% increase in revenue to $1.242 million from $28 thousand
a year ago, according to the mean estimate from 4 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Lexicon Pharmaceuticals
Inc is
for a loss of 22 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Lexicon
Pharmaceuticals Inc is $4.00​, above​ its last closing price
of $2.44. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.21       -0.21      -0.21     Met     2.2
 Jun. 30 2023  -0.17       -0.17      -0.22     Missed  -25.9
 Mar. 31 2023  -0.18       -0.18      -0.17     Beat    5.2​
 Dec. 31 2022  -0.14       -0.13      -0.16     Missed  -19.4
 ​​Sep.        -0.14       -0.14      -0.13     Beat    6.7
 30 2022                                                
 Jun. 30 2022  -0.16       -0.16      -0.16     Met     -1.7​
 Mar. 31 2022  -0.17       -0.16      -0.16     Met     2.8
 Dec. 31 2021  -0.18       -0.18      -0.17     Beat    6.9
 This summary was machine generated February 27 at 11:05 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)